Analysts Set Expectations for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Jasper Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($4.24) for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15).

A number of other research firms have also recently commented on JSPR. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Finally, HC Wainwright cut their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Stock Up 5.4 %

Shares of NASDAQ:JSPR opened at $6.01 on Wednesday. Jasper Therapeutics has a 52 week low of $5.25 and a 52 week high of $31.01. The firm has a fifty day simple moving average of $18.28 and a two-hundred day simple moving average of $19.24. The stock has a market capitalization of $90.15 million, a P/E ratio of -1.27 and a beta of 2.18.

Institutional Trading of Jasper Therapeutics

Several large investors have recently made changes to their positions in JSPR. BNP Paribas Financial Markets boosted its holdings in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Jasper Therapeutics in the third quarter worth about $59,000. MetLife Investment Management LLC lifted its stake in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Jasper Therapeutics in the second quarter worth about $300,000. Finally, Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics in the third quarter worth about $251,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.